Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide and dendritic cell vaccines.

Craig L Slingluff1, Victor H Engelhard, Soldano Ferrone

  • 1Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA. cls8h@virginia.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 13, 2006
PubMed
Summary

Melanoma peptide vaccines have yielded disappointing results because cancer immunity is complex. Future cancer immunotherapies require comprehensive monitoring and patient-specific strategies for effective melanoma treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterizing the Mutational Landscape of In-Transit Melanoma Metastases.

Pigment cell & melanoma research·2026
Same author

Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority-Serving Hospitals.

Cancer medicine·2026
Same author

Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab).

Cancer research communications·2026
Same author

Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

Journal for immunotherapy of cancer·2026
Same author

Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine Adjuvants.

Vaccines·2026

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • The development of melanoma cancer vaccines has focused on targeting specific antigens, assuming a weak spontaneous immune response.
  • This approach has led to disappointing clinical outcomes in melanoma therapy.

Observation:

  • The host-tumor relationship in melanoma is a complex interplay involving immune responses, immune escape, and immune adaptation.
  • Cancer immunity is more intricate than a simple deficiency in response to defined antigens.

Findings:

  • Current melanoma vaccine strategies are insufficient due to the multifaceted nature of tumor immunology.
  • Effective cancer immunotherapy necessitates a deeper understanding of immune regulatory processes.

Implications:

Related Experiment Videos

  • Future melanoma treatments should involve comprehensive, real-time immune monitoring and patient-specific immunomodulation.
  • Clinical studies using defined peptide antigens are crucial for advancing melanoma vaccine development and understanding the host-tumor relationship.